- Resverlogix’s (RVX) research on apabetalone’s benefits to COVID-19 patients has been published in Cell, a prestigious scientific journal
- The article is titled “BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection”
- The company is planning an open-label study to assess apabetalone’s efficacy in the treatment of COVID-19
- Resverlogix is a clinical-stage biotechnology company
- Resverlogix (RVX) closed trading down 1.06 per cent at C$0.93 per share
Resverlogix’s (RVX) research on apabetalone’s benefits to COVID-19 patients has been published in Cell, a prestigious scientific journal.
The article is titled “BET Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection”.
Donald McCaffrey, President and CEO of Resverlogix, commented,
“Inclusion in such a prestigious publication is a reflection of both the high quality of the research work, and its importance to the global scientific and medical community.
This collaborative research effort, employing state-of-the-art methods, has demonstrated apabetalone’s potential in preventing organ damage resulting from COVID-19 and provided a strong rationale for our upcoming human trials.”
Resverlogix’s pre-clinical research revealed that apabetalone may prevent SARS-CoV-2 from infecting human cells and reduce the inflammation and cytokine storm response which can result in organ damage and long-term negative impacts.
As a result of its dual mechanism and clinical safety record, several peer-reviewed publications have shortlisted apabetalone as a clinical candidate for COVID-19.
Apabetalone is currently an investigational phase 3 clinical candidate with safety data in more than 4,000 subjects.
The company is planning an open-label study to assess its safety and efficacy in the treatment of COVID-19.
Resverlogix is a clinical-stage biotechnology company.
Resverlogix (RVX) closed trading down 1.06 per cent at C$0.93 per share.
